13. Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


Clinical trials : 3,340 Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04815967
(ClinicalTrials.gov)
November 16, 202111/2/2021Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb SpasticityPhase 2/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC in Treatment of Adult Upper Limb Spasticity and Open-Label Extension, Multiple-Treatment Safety Study of MYOBLOCSpasticity;Cerebrovascular Accident;Multiple Sclerosis;Traumatic Brain Injury;Cervical Spinal Cord Injury;Cerebral PalsyDrug: Phase 2; Low Dose MYOBLOC; High Dose MYOBLOC; Placebo;Drug: Phase 3; MYOBLOCSupernus Pharmaceuticals, Inc.Solstice NeurosciencesActive, not recruiting18 Years80 YearsAll272Phase 2/Phase 3United States;Czechia